Analysis and significance of anti-latent membrane protein-1 antibodies in the sera of patients with EBV-associated diseases

Journal of Immunology

Volumn 164, Issue 5, 2000, Pages 2815-2822

  Xu, Jingwu ^a   Ahmad, Ali ^a   D'Addario, Mario ^a   Knafo, Laurent ^a   Jones, James F ^b   Prasad, U ^c   Dolcetti, R ^d   Vaccher, E ^d   Menezes, José ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c UNIVERSITY OF MALAYA   (Malaysia)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; MEMBRANE PROTEIN; VIRUS PROTEIN;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; LYMPHOPROLIFERATIVE DISEASE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION;

EID: 0034163314     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.5.2815     Document Type: Article

References (51)

1. Kieff, E. 1996. Epstein-Barr virus and its replication. In Fields Virology, B. N. Fields, D. M. Knipe, and P. M. Howley, eds. Lippincott-Raven, Philadelphia, p. 2343-2396.
2. Rickinson, A. B., and E. Kieff. 1996. Epstein-Barr virus. In Fields Virology, B. N. Fields, D. M. Knipe, and P. M. Howley, eds. Lippincott-Raven, Philadelphia, p. 2397-2446.
3. Liebowitz, D. 1994. Nasopharyngeal carcinoma: the Epstein-Barr virus association. Semin. Oncol. 21:376.
4. Henderson, S., M. Rowe, C. Gregory, D. Croom-Carter, F. Wang, R. Longnecker, E. Kieff, and A. Rickinson. 1991. Induction of Bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65:1107.
5. Erickson, K. D., and J. M. Martin. 1997. Early detection of the lytic LMP-1 protein in EBV-infected B cells suggests its presence in the virion. Virology 284:1.
6. Eliopoulos, A. G., and A. B. Rickinson. 1998. Epstein-Barr virus: LMP1 masquarades as an active receptor. Curr. Biol. 8:R196.
7. Eliopoulos, A. G., S. M. Blake, J. E. Floettmann, M. Rowe, and L. S. Young. 1999. Epstein-Barr virus encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF 2. J. Virol. 73:1023.
8. Miller, W. E., G. Mosialos, E. Kieff, and N. Raab-Traub. 1997. Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-κB activation. J. Virol. 71:586.
9. Mosialos, G., M. Birkenbach, R. Yalamanchili, T. vanArsdale, C. Ware, and E. Kieff. 1995. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80:389.
10. Devergne, O., E. Hatzivassiliou, K. M. Izumi, K. M. Kaye, M. F. Kleijnen, E. Kieff, and G. Mosialos. 1996. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-κB activation. Mol. Cell. Biol. 16:7098.
11. Sandberg, M., W. Hammerschmidt, and B. Sugden. 1997. Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3. J. Virol. 71:4649.
12. Kaye, K. M., K. M. Izumi, and E. Kieff. 1993. Epstein-Barr virus latent membrane protein 1 is essential for B lymphocyte transformation. Proc. Natl. Acad. Sci. USA 90:9150.
13. Wang, F., C. Gregory, C. Sample, M. Rowe, D. Liebowitz, R. Murray, A. Rickinson, and E. Kieff. 1990. Epstein-Barr virus latent-membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol. 64:2309.
14. Rowe, M., M. Peng-Pilon, and D. S. Huen. 1994. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B cell-specific response that is delayed relative to NF-κB activation and to induction of cell surface markers. J. Virol. 68:5602.
15. Arvanitakis, L., N. Yaseen, and S. Sharma. 1995. Latent-membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-β1-mediated growth inhibition in EBV-positive B cells. J. Immunol. 155:1047.
16. Khanna, R., S. R. Burrows, and D. J. Moss. 1995. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol. Rev. 59:387.
17. Rickinson, A. B., and J. D. Moss. 1997. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 15:405.
18. Menezes, J., W. Leibold, G. Klein, and G. Clements. 1975. Establishment and characterization of an Epstein-Barr virus (EBV)-negative lymphoblastoid cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt lymphoma. Biomedicine 22:276.
19. Ahmad, A., A. Ladha, E. A. Cohen, and J. Menezes. 1993. Stable expression of the transfected HIV-1 env gene in a human B cell line: characterization of gp120-expressing clones and immunobiological studies. Virology 192:447.
20. Xu, J., A. Ahmad, M. Blagdon, M. D'Addario, J. F. Jones, R. Dolcetti, E. Vaccher, U. Prasad, and J. Menezes. 1998. The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases. Int. J. Cancer 79:481.
21. Xu, J., J. Menezes, U. Prasad, and A. Ahmad. 1999. Elevated serum levels of transforming growth factor β1 in the Epstein-Barr virus-associated nasopharyngeal carcinoma patients. Int. J. Cancer 84:396.
22. Teo, P. M. L., D. N. Leibowitz, and R. R. A. Weichselbaum. 1991. Proposed modification of the Ho stage-classification for nasopharyngeal carcinoma. Radiol. Oncol. 21:11.
23. Tanner, J. E., M. X. Wei, C. Alfieri C, A. Ahmad, P. Tailor, T. Ooka, and J. Menezes. 1997. Antibody and antibody-dependent cellular cytotoxicity (ADCC) responses against the BamHIA rightward open reading frame-1 (BARF-1) protein of Epstein-Barr virus (EBV) in EBV-associated disorders. J. Infect. Dis. 175:38.
24. Xu, J. W., A. Ahmad, U. Prasad, and J. Menezes. 1998. Clinical relevance of IgA antibodies to the Epstein-Barr virus envelope glycoprotein gp350 in the sera of nasopharyngeal carcinoma patients. J. Clin. Microbiol. 36:3740.
25. Modrow, S., and H. Wolf. 1986. Characterization of two related Epstein-Barr virus-encoded membrane proteins that are differentially expressed in Burkitt's lymphoma and in vitro transformed cell lines. Proc. Natl. Acad. Sci. USA 83: 5703.
26. Dillner, J., R. Szigeti, W. Henle, R. A. Lerner, and G. Klein. 1987. Cellular and humoral immune responses to synthetic peptides deduced from the amino-acid sequences of Epstein-Barr virus-encoded proteins in EBV-transformed cells. Int. J. Cancer 40:455.
27. Rowe, M., J. Finke, R. Szigeti, and G. Klein. 1988. Characterization of the serological response in man to the latent membrane protein and the six nuclear antigens encoded by Epstein-Barr virus. J. Gen. Virol. 69:1217.
28. Chen, H.-F., S. Kevan-Jah, K.-O. Suentzenich, F. A. Grasser, and N. Muller-Lantzsch. 1992. Expression of the Epstein-Barr virus latent membrane protein (LMP) in insect cells and detection of antibodies in human sera against this protein. Virology 190:106.
29. Meji, P., M. B. H. J. Vervoort, J. Aarbiou, P. van Dissel, A. Brink, E. Bloemena, C. J. L. M. Meijer, and J. M. Middledrop. 1999. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases. J. Inf. Dis. 179:1108.
30. Smith, G. E., M. D. Summers, and M. J. Fraser. 1987. Production of human β-interferon in insect cells infected with a baculovirus expression vector. Mol. Cell. Biol.3:2156.
31. Levine, P. H., G. Pallesen, P. Ebbesen, N. Harris, A. S. Evans, and N. Mueller. 1994. Evaluation of Epstein-Barr virus antibody patterns and detection of viral markers in the biopsies of patients with Hodgkin's disease. Int. J. Cancer 59:48.
32. Rowe, M., H. S. Evans, L. S. Young, K. Hennessy, E. Kieff, and A. B. Rickinson. 1987. Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. J. Gen. Virol. 68:1575.
33. Mann, K. P., D. Staunton, and D. A. Thorley-Lawson. 1985. Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J. Virol. 55: 710.
34. Pathmanathan, R., U. Prasad, R. Sadler, K. Flynn, and N. Raab-Traub. 1995. Clonal proliferation of cells infected with Epstein-Barr virus in pre-invasive lesions related to nasopharyngeal carcinoma. N. Engl. J. Med. 333:693.
35. Dawson, C. W., A. B. Rickinson, and L. S. Young. 1990. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 344:777.
36. Kenney, J. L., M. E. Guinness, T. Curiel, and J. Lacy. 1998. Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in EBV-immortalized B cells. Blood 92:1721.
37. Floettmann, J. E., K. Ward, A. B. Rickinson, and M. Row. 1996. Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline-related expression in B cell lines. Virology. 223:29.
38. Hammerschmidt, M., B. Sudgen, and V. R. Baichwal. 1989. The transformation domain alone of the latent membrane protein of Epstein-Barr virus is toxic to cells when expressed at high levels. J. Virol. 63:2469.
39. Cuomo, L., T. Ramquist, P. Trivedi, F. Wang, G. Klein, and M. G. Masucci. 1992. Expression of the Epstein-Barr virus (EBV)-encoded membrane protein LMP1 impairs the in vitro growth, clonability and tumorigenicity of an EBV-negative Burkitt lymphoma line. Int. J. Cancer 51:949.
40. Hu, L.-F., F. Chen, Q-F. Zhen, Y. W. Zhang, Y. Luo, X. Zheng, G. Winberg, I. Ernberg, and G. Klein. 1995. Differences in the growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomas. Eur. J. Cancer 31A:658.
41. Cuomo, L., P. Trivedi, F. Wang, G. Wimberg, G. Klein, and M. Masucci. 1990. Expression of the Epstein-Barr virus (EBV)-encoded membrane antigen LMP increases the stimulatory capacity of EBV negative B lymphoma lines in allogeneic mixed lymphocyte cultures. Ear. J. Immunol. 20:2293.
42. Agathanggelou, A., G. Niedobitek, R. Chen, J. Nicholls, W. Yin, and L. S. Young. 1995. Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma: evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells. Am. J. Pathol. 147:1152.
43. Murray, P. G., C. M. Constandinou, J. Crocker, L. S. Young, and R. F. Ambinder. 1998. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood 92:2477.
44. Cherney, B. W., C. Sgadari, C. Kanegane, F. Wang, and G. Tosato. 1998. Expression of the Epstein-Barr virus protein LMP1 mediated tumor regression in vivo. Blood. 91:2491.
45. Trividi, P., L. F. Hu, F. Chen, B. Christensson, M. G. Masucci, G. Klein, and G. Winberg. 1994. Epstein-Barr virus (EBV)-encoded membrane protein LMPI from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. Eur. J. Cancer 30A:84.
46. Knecht, H., E. Buchmann, P. Brousset, S. Rothenherger, H. Einsek, V. S. Lestou, G. Delsol, F. Buchmann, P. F. Ambros, and B. F. Odermatt. 1995. Mutational hot spots within the carboxy terminal region of the LMP1 oncogene of Epstein-Barr virus are frequent in lymphoproliferative disorders. Oncogene 10:523.
47. Dolcetti, R., P. Zancai, V. D. Re, A. Gloghini, B. Bigoni, B. Pivetta, S. D. Vita, A. Carbone, and M. Boiocchi. 1997. Epstein-Barr virus strains with latent membrane protein-1 deletions: prevalence in the Italian population and high association with human immunodeficiency virus-related Hodgkin's disease. Blood 89: 1723.
48. Sandvej, K., J. W. Gratama, M. Munch, X.-G. Zhou, R. L. H. Bolhuis, B. S. Andersen, N. Gregersen, and S. Hamilton-Dutoit. 1997. Sequence analysis of the Epstein-Barr virus (EBV) latent membrane protein-1 gene and promoter region: identification of four variants among wild-type EBV isolates. Blood 90: 323.
49. Hu, L. F., E. R. Zabarovky, F. Chen, S. L. Cao, I. Ernberg, G. Klein, and G. Winberg. 1991. Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP-1) from a Chinese nasopharyngeal carcinoma. J. Gen. Virol. 72:2399.
50. Chen, M. L., C. N. Tsai, C. L. Liang, C. S. Shu, C. R. Huang, D. Sulitzeanu, S. T. Liu, and Y. S. Chang. 1992. Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene 7:2131.
51. Li, S-N., Y-S. Chang, and S-T. Liu. 1996. Effect of a 10-amino acid deletion of the oncogenic activity of latent membrane protein 1 nf Epstein-Barr virus. Oncogene 12:2129.